NASDAQ:FMI - Foundation Medicine Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$92.70 +2.70 (+3.00 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$92.70
Today's Range$88.2583 - $93.60
52-Week Range$31.70 - $93.60
Volume371,102 shs
Average Volume304,095 shs
Market Capitalization$3.18 billion
P/E Ratio-20.60
Dividend YieldN/A
Beta-0.12

About Foundation Medicine (NASDAQ:FMI)

Foundation Medicine logoFoundation Medicine, Inc. provides various molecular information products in the United States. The company's molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic insights about each patient's individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted therapies and immunotherapies. It provides clinical products, such as FoundationOne for solid tumors; FoundationOne Heme for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and sarcomas; Foundation Assay for Circulating Tumor; FoundationFocus CDxBRCA, a diagnostic assay to aid in identifying women with ovarian cancer; and FoundationOne CDx, a diagnostic assay for solid tumors. The company also offers FoundationCORE, a knowledgebase to publish scientific and medical advances, and foster relationships throughout the oncology community. In addition, it has strategic collaboration agreements with F. Hoffmann-La Roche Ltd.; and Genentech, Inc. Foundation Medicine, Inc. has a collaboration with The European Organisation for Research and Treatment of Cancer to advance precision medicine using comprehensive genomic profiling to facilitate clinical trial enrollment. The company was founded in 2009 and is headquartered in Cambridge, Massachusetts. Foundation Medicine, Inc. is a subsidiary of Roche Holdings, Inc.

Receive FMI News and Ratings via Email

Sign-up to receive the latest news and ratings for FMI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FMI
CUSIPN/A
Phone617-418-2200

Debt

Debt-to-Equity Ratio4.76
Current Ratio2.27
Quick Ratio1.98

Price-To-Earnings

Trailing P/E Ratio-20.60
Forward P/E Ratio-21.46
P/E GrowthN/A

Sales & Book Value

Annual Sales$152.90 million
Price / Sales22.46
Cash FlowN/A
Price / CashN/A
Book Value$0.51 per share
Price / Book181.76

Profitability

EPS (Most Recent Fiscal Year)($4.50)
Net Income$-161,460,000.00
Net Margins-84.96%
Return on Equity-299.63%
Return on Assets-94.81%

Miscellaneous

Employees662
Outstanding Shares37,040,000

Foundation Medicine (NASDAQ:FMI) Frequently Asked Questions

What is Foundation Medicine's stock symbol?

Foundation Medicine trades on the NASDAQ under the ticker symbol "FMI."

How were Foundation Medicine's earnings last quarter?

Foundation Medicine (NASDAQ:FMI) announced its earnings results on Wednesday, May, 2nd. The company reported ($1.02) EPS for the quarter, beating the Zacks' consensus estimate of ($1.10) by $0.08. The firm had revenue of $52.84 million for the quarter, compared to analysts' expectations of $44.99 million. Foundation Medicine had a negative net margin of 84.96% and a negative return on equity of 299.63%. The company's quarterly revenue was up 100.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.31) EPS. View Foundation Medicine's Earnings History.

When is Foundation Medicine's next earnings date?

Foundation Medicine is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Foundation Medicine.

What price target have analysts set for FMI?

3 brokerages have issued 12-month price objectives for Foundation Medicine's stock. Their forecasts range from $73.00 to $90.00. On average, they anticipate Foundation Medicine's share price to reach $81.00 in the next year. View Analyst Ratings for Foundation Medicine.

Who are some of Foundation Medicine's key competitors?

Who are Foundation Medicine's key executives?

Foundation Medicine's management team includes the folowing people:
  • Mr. Alexis Borisy, Co-Founder, Founding Advisor & Independent Director (Age 46)
  • Mr. Troy Cox, CEO, Pres & Director (Age 54)
  • Mr. Jason Ryan, CFO & Principal Accounting Officer (Age 44)
  • Mr. Konstantin Fiedler, Chief Operating Officer (Age 52)
  • Mr. Tom Godden, Chief Information Officer

Has Foundation Medicine been receiving favorable news coverage?

News articles about FMI stock have been trending somewhat positive on Friday, Accern reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Foundation Medicine earned a coverage optimism score of 0.21 on Accern's scale. They also gave press coverage about the company an impact score of 46.65 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Foundation Medicine's major shareholders?

Foundation Medicine's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.71%), Lord Abbett & CO. LLC (1.66%), Baillie Gifford & Co. (1.05%), Amundi Pioneer Asset Management Inc. (0.74%), Elk Creek Partners LLC (0.37%) and Highbridge Capital Management LLC (0.29%). Company insiders that own Foundation Medicine stock include David Daly, Evan/ Fa Jones, Jason Ryan, Konstantin Fiedler, Krishna Yeshwant, Michael J Doherty, Michael J Pellini, Robert W Hesslein, Steven J Kafka, Troy Cox and Vincent A Miller. View Institutional Ownership Trends for Foundation Medicine.

Which institutional investors are selling Foundation Medicine stock?

FMI stock was sold by a variety of institutional investors in the last quarter, including Bamco Inc. NY, BlackRock Inc., Pier Capital LLC, Platinum Investment Management Ltd., Employees Retirement System of Texas, A.R.T. Advisors LLC, California Public Employees Retirement System and DekaBank Deutsche Girozentrale. Company insiders that have sold Foundation Medicine company stock in the last year include David Daly, Evan/ Fa Jones, Jason Ryan, Konstantin Fiedler, Krishna Yeshwant, Michael J Doherty, Michael J Pellini, Robert W Hesslein, Steven J Kafka, Troy Cox and Vincent A Miller. View Insider Buying and Selling for Foundation Medicine.

Which institutional investors are buying Foundation Medicine stock?

FMI stock was bought by a variety of institutional investors in the last quarter, including Elk Creek Partners LLC, Highbridge Capital Management LLC, PointState Capital LP, Franklin Resources Inc., Baillie Gifford & Co., UBS Group AG, Trexquant Investment LP and Lord Abbett & CO. LLC. View Insider Buying and Selling for Foundation Medicine.

How do I buy shares of Foundation Medicine?

Shares of FMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Foundation Medicine's stock price today?

One share of FMI stock can currently be purchased for approximately $92.70.

How big of a company is Foundation Medicine?

Foundation Medicine has a market capitalization of $3.18 billion and generates $152.90 million in revenue each year. The company earns $-161,460,000.00 in net income (profit) each year or ($4.50) on an earnings per share basis. Foundation Medicine employs 662 workers across the globe.

How can I contact Foundation Medicine?

Foundation Medicine's mailing address is 150 Second Street, Cambridge MA, 02141. The company can be reached via phone at 617-418-2200 or via email at [email protected]


MarketBeat Community Rating for Foundation Medicine (FMI)

Community Ranking:  1.5 out of 5 (star half star)
Outperform Votes:  132 (Vote Outperform)
Underperform Votes:  297 (Vote Underperform)
Total Votes:  429
MarketBeat's community ratings are surveys of what our community members think about Foundation Medicine and other stocks. Vote "Outperform" if you believe FMI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FMI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Foundation Medicine (NASDAQ:FMI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Foundation Medicine in the last 12 months. Their average twelve-month price target is $81.00, suggesting that the stock has a possible downside of 12.62%. The high price target for FMI is $90.00 and the low price target for FMI is $73.00. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyBuy
Consensus Rating Score: 2.332.502.602.67
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $81.00$70.50$58.25$35.00
Price Target Upside: 12.62% downside15.32% downside11.20% downside5.42% upside

Foundation Medicine (NASDAQ:FMI) Consensus Price Target History

Price Target History for Foundation Medicine (NASDAQ:FMI)

Foundation Medicine (NASDAQ:FMI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/8/2018Wells Fargo & CoReiterated RatingMarket Perform ➝ Market Perform$67.00 ➝ $80.00HighView Rating Details
2/15/2018CowenInitiated CoverageOutperform$90.00MediumView Rating Details
1/29/2018Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$73.00LowView Rating Details
5/15/2017BTIG ResearchUpgradeNeutral ➝ Buy$39.00HighView Rating Details
4/3/2017William BlairReiterated RatingBuyLowView Rating Details
3/7/2017Janney Montgomery ScottUpgradeSell ➝ Neutral$31.00N/AView Rating Details
11/3/2016BenchmarkDowngradeBuy ➝ HoldN/AView Rating Details
9/21/2016UBSBoost Price TargetNeutral$16.00 ➝ $22.00N/AView Rating Details
8/3/2016JPMorgan Chase & Co.Reiterated RatingHold$25.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Foundation Medicine (NASDAQ:FMI) Earnings History and Estimates Chart

Earnings by Quarter for Foundation Medicine (NASDAQ:FMI)

Foundation Medicine (NASDAQ:FMI) Earnings Estimates

2018 EPS Consensus Estimate: ($4.27)
2019 EPS Consensus Estimate: ($3.60)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.11)($1.11)($1.11)
Q2 20181($1.08)($1.08)($1.08)
Q3 20181($1.06)($1.06)($1.06)
Q4 20181($1.02)($1.02)($1.02)
Q1 20191($1.03)($1.03)($1.03)
Q2 20191($0.90)($0.90)($0.90)
Q3 20191($0.87)($0.87)($0.87)
Q4 20191($0.80)($0.80)($0.80)

Foundation Medicine (NASDAQ FMI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/30/2018($1.05)N/AView Earnings Details
5/2/2018Q1 2018($1.10)($1.02)$44.99 million$52.84 millionViewListenView Earnings Details
3/7/2018Q4 2017($0.97)($1.05)$48.69 million$48.90 millionViewListenView Earnings Details
11/1/2017Q3 2017($1.06)($0.90)$37.99 million$42.66 millionViewN/AView Earnings Details
8/1/2017Q2 2017($1.08)($1.24)$34.94 million$35.00 millionViewListenView Earnings Details
5/9/2017Q1 2017($1.02)($1.31)$29.07 million$26.32 millionViewListenView Earnings Details
2/22/2017Q416($0.96)($1.02)$29.23 million$28.80 millionViewListenView Earnings Details
11/2/2016Q316($0.88)($0.90)$28.70 million$29.43 millionViewN/AView Earnings Details
8/2/2016Q216($0.79)($0.84)$26.72 million$28.24 millionViewN/AView Earnings Details
5/3/2016Q116($0.72)($0.50)$25.20 million$30.40 millionViewN/AView Earnings Details
2/23/2016Q415($0.67)($0.55)$25.76 million$26.10 millionViewListenView Earnings Details
11/3/2015Q315($0.56)($0.60)$24.04 million$25.40 millionViewListenView Earnings Details
7/29/2015Q215($0.56)($0.98)$24.44 million$22.50 millionViewListenView Earnings Details
5/11/2015Q115($0.53)($0.59)$21.00 million$19.30 millionViewListenView Earnings Details
2/24/2015Q314($0.53)($0.47)$18.05 million$18.70 millionViewListenView Earnings Details
11/5/2014Q3($0.49)($0.46)$15.60 million$16.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.50)($0.49)$13.39 million$14.50 millionViewN/AView Earnings Details
5/7/2014Q114($0.48)($0.44)$11.33 million$11.45 millionViewN/AView Earnings Details
2/25/2014Q413($0.43)($0.48)$9.01 million$9.66 millionViewN/AView Earnings Details
11/6/2013($0.51)($3.51)$6.92 million$8.20 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Foundation Medicine (NASDAQ:FMI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Foundation Medicine (NASDAQ FMI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.00%
Institutional Ownership Percentage: 32.86%
Insider Trading History for Foundation Medicine (NASDAQ:FMI)
Institutional Ownership by Quarter for Foundation Medicine (NASDAQ:FMI)

Foundation Medicine (NASDAQ FMI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/21/2018Vincent A MillerInsiderSell1,570$85.00$133,450.00View SEC Filing  
5/16/2018Troy CoxCEOSell2,157$77.10$166,304.70View SEC Filing  
5/7/2018Troy CoxCEOSell7,063$70.01$494,480.63245,627View SEC Filing  
4/16/2018Jason RyanCFOSell3,449$74.30$256,260.7052,573View SEC Filing  
4/16/2018Michael J PelliniDirectorSell3,500$74.65$261,275.00110,711View SEC Filing  
4/16/2018Vincent A MillerInsiderSell3,283$74.02$243,007.6670,088View SEC Filing  
4/3/2018Michael J PelliniDirectorSell13,659$70.28$959,954.52114,211View SEC Filing  
4/2/2018Jason RyanCFOSell6,139$76.23$467,975.97View SEC Filing  
4/2/2018Konstantin FiedlerCOOSell358$74.88$26,807.04View SEC Filing  
4/2/2018Michael J. DohertyInsiderSell8,190$74.87$613,185.30View SEC Filing  
4/2/2018Robert W HessleinSVPSell1,585$74.88$118,684.80View SEC Filing  
3/15/2018Jason RyanCFOSell15,000$78.26$1,173,900.00View SEC Filing  
3/15/2018Michael J PelliniDirectorSell3,500$78.29$274,015.00View SEC Filing  
2/20/2018Vincent A MillerInsiderSell32,008$76.87$2,460,454.96View SEC Filing  
2/15/2018Jason RyanCFOSell15,000$67.53$1,012,950.00View SEC Filing  
2/15/2018Michael J PelliniDirectorSell17,324$67.69$1,172,661.56View SEC Filing  
2/15/2018Troy CoxCEOSell9,012$67.22$605,786.64View SEC Filing  
2/13/2018Steven J KafkaCOOSell29,791$61.55$1,833,636.05View SEC Filing  
2/7/2018Steven J KafkaCOOSell23,064$70.13$1,617,478.3261,361View SEC Filing  
2/7/2018Troy CoxCEOSell26,713$70.13$1,873,382.69224,345View SEC Filing  
1/29/2018Vincent A MillerInsiderSell4,400$75.00$330,000.0097,722View SEC Filing  
1/22/2018Vincent A MillerInsiderSell17,187$70.27$1,207,730.49110,509View SEC Filing  
1/17/2018Michael J PelliniDirectorSell37,288$64.55$2,406,940.40View SEC Filing  
1/17/2018Vincent A MillerInsiderSell14,755$65.31$963,649.05View SEC Filing  
1/16/2018Jason RyanCFOSell21,035$64.38$1,354,233.30View SEC Filing  
1/16/2018Robert W HessleinSVPSell18,021$64.30$1,158,750.30View SEC Filing  
1/16/2018Steven J KafkaCOOSell4,148$65.71$272,565.08View SEC Filing  
1/2/2018Jason RyanCFOSell2,336$64.00$149,504.00View SEC Filing  
1/2/2018Robert W. HessleinSVPSell1,864$64.00$119,296.00View SEC Filing  
1/2/2018Steven J. KafkaCOOSell157$64.00$10,048.00View SEC Filing  
1/2/2018Vincent A MillerInsiderSell2,349$64.00$150,336.0099,484View SEC Filing  
12/13/2017Evan/ Fa JonesDirectorSell1,400$62.05$86,870.0017,652View SEC Filing  
12/6/2017Evan/ Fa JonesDirectorSell6,500$60.66$394,290.0019,652View SEC Filing  
12/6/2017Steven J KafkaCOOSell5,774$58.57$338,183.1896,761View SEC Filing  
12/5/2017Jason RyanCFOSell21,726$61.26$1,330,934.7655,639View SEC Filing  
12/5/2017Vincent A MillerInsiderSell20,000$61.17$1,223,400.0099,984View SEC Filing  
11/2/2017Jason RyanCFOSell9,731$50.00$486,550.0052,601View SEC Filing  
10/13/2017Steven J KafkaCOOSell3,361$44.62$149,967.82View SEC Filing  
10/12/2017Jason RyanCFOSell1,152$45.05$51,897.60View SEC Filing  
10/2/2017Jason RyanCFOSell3,154$38.80$122,375.20View SEC Filing  
10/2/2017Michael J PelliniDirectorSell4,349$38.80$168,741.20View SEC Filing  
10/2/2017Robert W HessleinSVPSell2,165$38.80$84,002.00View SEC Filing  
10/2/2017Steven J KafkaCOOSell3,201$38.80$124,198.80View SEC Filing  
10/2/2017Vincent A MillerInsiderSell2,944$38.80$114,227.20View SEC Filing  
8/9/2017David DalyInsiderSell46,872$39.50$1,851,444.00163,133View SEC Filing  
8/9/2017Michael J PelliniDirectorSell30,000$39.52$1,185,600.00275,077View SEC Filing  
8/8/2017Krishna YeshwantDirectorSell4,800$40.01$192,048.005,786View SEC Filing  
8/4/2017Krishna YeshwantDirectorSell18,072$36.85$665,953.205,786View SEC Filing  
7/14/2017Steven J KafkaCOOSell11,781$39.15$461,226.1597,549View SEC Filing  
7/13/2017Jason RyanCFOSell5,084$39.77$202,190.6866,638View SEC Filing  
7/6/2017David DalyInsiderSell6,316$38.84$245,313.44View SEC Filing  
7/6/2017Jason RyanCFOSell6,683$38.84$259,567.72View SEC Filing  
7/6/2017Michael J. PelliniDirectorSell15,856$38.84$615,847.04View SEC Filing  
7/6/2017Robert W. HessleinSVPSell5,070$38.84$196,918.80View SEC Filing  
7/6/2017Steven J KafkaCOOSell19,708$38.93$767,232.44116,728View SEC Filing  
7/5/2017Steven J KafkaCOOSell12,310$38.98$479,843.80116,728View SEC Filing  
6/2/2017Jason RyanCFOSell5,573$40.00$222,920.0078,405View SEC Filing  
6/1/2017David DalyInsiderSell555$38.30$21,256.50View SEC Filing  
4/18/2017Jason RyanCFOSell503$34.55$17,378.6551,244View SEC Filing  
4/18/2017Steven J KafkaCOOSell4,405$34.55$152,192.75129,038View SEC Filing  
4/3/2017David DalyInsiderSell2,070$31.96$66,157.20View SEC Filing  
4/3/2017Michael J. PelliniDirectorSell1,700$31.96$54,332.00View SEC Filing  
4/3/2017Robert W. HessleinSVPSell1,233$31.96$39,406.68View SEC Filing  
4/3/2017Steven J. KafkaCOOSell2,157$31.96$68,937.72View SEC Filing  
3/16/2017Jason RyanCFOSell12,500$31.68$396,000.0056,230View SEC Filing  
3/16/2017Robert W HessleinSVPSell6,231$31.67$197,335.77104,305View SEC Filing  
3/8/2017Michael J PelliniDirectorSell40,000$34.30$1,372,000.00353,144View SEC Filing  
2/8/2017Steven J KafkaCOOSell10,415$23.24$242,044.60146,015View SEC Filing  
1/13/2017Jason RyanCFOSell1,777$19.00$33,763.0052,980View SEC Filing  
1/4/2017David DalyInsiderSell5,097$17.91$91,287.27View SEC Filing  
1/4/2017Jason RyanCFOSell4,665$17.74$82,757.10View SEC Filing  
1/4/2017Michael J. PelliniCEOSell14,637$17.67$258,635.79View SEC Filing  
1/4/2017Robert W. HessleinSVPSell4,682$17.74$83,058.68View SEC Filing  
1/4/2017Steven J. KafkaCOOSell8,390$17.72$148,670.80View SEC Filing  
12/1/2016David DalyInsiderSell564$19.95$11,251.80View SEC Filing  
11/22/2016Steven J KafkaCOOSell6,273$23.01$144,341.73103,009View SEC Filing  
10/20/2016Jason RyanCFOSell506$22.45$11,359.7059,422View SEC Filing  
10/20/2016Steven J KafkaCOOSell4,427$23.00$101,821.00101,550View SEC Filing  
10/4/2016David DalyInsiderSell2,045$23.65$48,364.25View SEC Filing  
10/4/2016Michael J. PelliniCEOSell2,629$23.65$62,175.85View SEC Filing  
10/4/2016Robert W. HessleinSVPSell1,220$23.65$28,853.00View SEC Filing  
10/4/2016Steven J. KafkaCOOSell2,135$23.62$50,428.70View SEC Filing  
9/20/2016Steven J KafkaCOOSell9,469$23.70$224,415.30108,112View SEC Filing  
8/19/2016Jason RyanCFOSell13,863$23.92$331,602.9661,148View SEC Filing  
7/5/2016David DalyInsiderSell5,008$17.76$88,942.08View SEC Filing  
7/5/2016Jason RyanCFOSell4,687$17.63$82,631.81View SEC Filing  
7/5/2016Michael J. PelliniCEOSell10,160$17.63$179,120.80View SEC Filing  
7/5/2016Robert W. HessleinSVPSell4,705$17.62$82,902.10View SEC Filing  
7/5/2016Steven J. KafkaCOOSell6,495$17.67$114,766.65View SEC Filing  
6/3/2016David DalyInsiderSell472$21.66$10,223.52114,458View SEC Filing  
4/1/2016Steven J KafkaCOOSell124$18.08$2,241.9241,226View SEC Filing  
4/1/2016Vincent A MillerInsiderSell356$18.08$6,436.4878,482View SEC Filing  
12/1/2015David DalyInsiderSell2,559$16.78$42,940.0245,631View SEC Filing  
11/13/2015Michael J PelliniCEOBuy9,100$16.43$149,513.00174,025View SEC Filing  
6/15/2015Krishna YeshwantDirectorSell183,860$32.98$6,063,702.80View SEC Filing  
4/7/2015Alexis BorisyDirectorSell234,542$50.00$11,727,100.00View SEC Filing  
4/7/2015Roche Holdings IncInsiderBuy15,604,288$50.00$780,214,400.00View SEC Filing  
4/7/2015Rock Ventures Lp ThirdMajor ShareholderSell3,976,278$50.00$198,813,900.00View SEC Filing  
3/5/2015Michael J PelliniCEOSell153,300$47.24$7,241,892.00View SEC Filing  
1/15/2015Steven J KafkaCOOSell15,000$48.38$725,700.00View SEC Filing  
1/12/2015Michael J PelliniCEOSell22,500$51.07$1,149,075.00View SEC Filing  
1/12/2015Robert W HessleinSVPSell7,000$52.11$364,770.00View SEC Filing  
1/12/2015Steven J KafkaCOOSell8,000$51.83$414,640.00View SEC Filing  
1/12/2015Vincent A MillerInsiderSell2,000$53.03$106,060.00View SEC Filing  
1/8/2015Robert W HessleinSVPSell4,000$23.03$92,120.00View SEC Filing  
12/29/2014Michael J PelliniCEOSell12,500$23.91$298,875.00View SEC Filing  
11/17/2014Jason RyanSVPSell3,541$24.90$88,170.90View SEC Filing  
11/14/2014Michael J PelliniCEOSell12,500$24.91$311,375.00View SEC Filing  
10/27/2014Jason RyanSVPSell2,360$25.00$59,000.00View SEC Filing  
10/27/2014Steven J KafkaCOOSell10,000$25.31$253,100.00View SEC Filing  
9/15/2014Jason RyanSVPSell2,361$21.92$51,753.12View SEC Filing  
8/18/2014Michael J PelliniCEOSell12,500$25.29$316,125.00View SEC Filing  
7/22/2014Steven J KafkaCOOSell10,000$27.14$271,400.00View SEC Filing  
7/15/2014Jason RyanSVPSell3,541$27.22$96,386.02View SEC Filing  
7/15/2014Vincent A MillerInsiderSell15,000$27.25$408,750.00View SEC Filing  
7/8/2014Robert W HessleinSVPSell4,000$27.22$108,880.00View SEC Filing  
7/2/2014Michael J PelliniCEOSell15,000$27.42$411,300.00View SEC Filing  
6/26/2014Jason RyanSVPSell1,180$25.00$29,500.00View SEC Filing  
6/26/2014Steven J KafkaCOOSell5,000$25.19$125,950.00View SEC Filing  
6/19/2014Steven J KafkaCOOSell5,000$24.46$122,300.00View SEC Filing  
6/16/2014Jason RyanSVPSell2,361$22.61$53,382.21View SEC Filing  
6/13/2014Krishna YeshwantDirectorSell1,300,000$22.40$29,120,000.00View SEC Filing  
6/5/2014Jason RyanSVPSell10,000$24.06$240,600.00View SEC Filing  
6/5/2014Steven J KafkaCOOSell4,500$24.19$108,855.00View SEC Filing  
5/6/2014Vincent MillerInsiderSell3,000$30.00$90,000.00117,000View SEC Filing  
4/16/2014Jason RyanSVPSell3,541$26.36$93,340.76View SEC Filing  
4/16/2014Vincent MillerInsiderSell30,000$26.86$805,800.00120,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Foundation Medicine (NASDAQ FMI) News Headlines

Source:
DateHeadline
Foundation Medicine (FMI) Expected to Earn Q1 2019 Earnings of ($1.03) Per ShareFoundation Medicine (FMI) Expected to Earn Q1 2019 Earnings of ($1.03) Per Share
www.americanbankingnews.com - May 24 at 9:26 AM
Foundation Medicine Establishes Immuno-Oncology Companion Diagnostics Collaboration with MerckFoundation Medicine Establishes Immuno-Oncology Companion Diagnostics Collaboration with Merck
finance.yahoo.com - May 24 at 8:31 AM
Foundation Medicine teams up with Merck to develop companion diagnostic tests for KeytrudaFoundation Medicine teams up with Merck to develop companion diagnostic tests for Keytruda
seekingalpha.com - May 24 at 7:37 AM
Foundation Medicine (FMI) Insider Sells $133,450.00 in StockFoundation Medicine (FMI) Insider Sells $133,450.00 in Stock
www.americanbankingnews.com - May 23 at 8:16 PM
3 Things In Biotech, May 22: Breast Cancer Disruption!3 Things In Biotech, May 22: Breast Cancer Disruption!
seekingalpha.com - May 23 at 5:24 PM
Todays Research Reports on Trending Tickers: Celgene and Foundation MedicineToday's Research Reports on Trending Tickers: Celgene and Foundation Medicine
finance.yahoo.com - May 22 at 5:25 PM
Foundation Medicine Receives New ADLT Status for FoundationOne CDx™ from the Centers for Medicare and Medicaid Services (CMS)Foundation Medicine Receives New ADLT Status for FoundationOne CDx™ from the Centers for Medicare and Medicaid Services (CMS)
finance.yahoo.com - May 21 at 8:39 AM
Foundation Medicine (FMI) Lifted to "Buy" at BidaskClubFoundation Medicine (FMI) Lifted to "Buy" at BidaskClub
www.americanbankingnews.com - May 18 at 5:07 PM
Troy Cox Sells 2,157 Shares of Foundation Medicine (FMI) StockTroy Cox Sells 2,157 Shares of Foundation Medicine (FMI) Stock
www.americanbankingnews.com - May 17 at 8:17 PM
FMI Crosses Above Average Analyst TargetFMI Crosses Above Average Analyst Target
www.nasdaq.com - May 17 at 5:22 PM
Analyzing Foundation Medicine (FMI) and Biocept (BIOC)Analyzing Foundation Medicine (FMI) and Biocept (BIOC)
www.americanbankingnews.com - May 16 at 12:13 PM
Foundation Medicine (FMI) Expected to Post Quarterly Sales of $50.96 MillionFoundation Medicine (FMI) Expected to Post Quarterly Sales of $50.96 Million
www.americanbankingnews.com - May 16 at 3:44 AM
Foundation Medicine (FMI) Receives Average Rating of "Buy" from AnalystsFoundation Medicine (FMI) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - May 15 at 1:38 AM
Foundation Medicine (FMI) Expected to Announce Earnings of -$1.11 Per ShareFoundation Medicine (FMI) Expected to Announce Earnings of -$1.11 Per Share
www.americanbankingnews.com - May 14 at 9:35 AM
Will Real World Performance Replace RCTs As Healthcares Most Important Standard?Will Real World Performance Replace RCTs As Healthcare's Most Important Standard?
www.forbes.com - May 11 at 9:18 AM
Foundation Medicine (FMI) Downgraded to "Hold" at BidaskClubFoundation Medicine (FMI) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - May 9 at 6:39 PM
Foundation Medicine (FMI) CEO Troy Cox Sells 7,063 SharesFoundation Medicine (FMI) CEO Troy Cox Sells 7,063 Shares
www.americanbankingnews.com - May 9 at 4:20 PM
Head to Head Comparison: Foundation Medicine (FMI) & Enzo Biochem (ENZ)Head to Head Comparison: Foundation Medicine (FMI) & Enzo Biochem (ENZ)
www.americanbankingnews.com - May 9 at 12:00 PM
Foundation Medicine (FMI) Upgraded to "Strong-Buy" by ValuEngineFoundation Medicine (FMI) Upgraded to "Strong-Buy" by ValuEngine
www.americanbankingnews.com - May 4 at 12:12 AM
Foundation Medicine (FMI) Posts Quarterly  Earnings Results, Beats Expectations By $0.08 EPSFoundation Medicine (FMI) Posts Quarterly Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - May 3 at 7:29 PM
Noteworthy Thursday Option Activity: ANET, FMI, CELGNoteworthy Thursday Option Activity: ANET, FMI, CELG
www.nasdaq.com - May 3 at 5:22 PM
Foundation Medicines (FMI) CEO Troy Cox on Q1 2018 Results - Earnings Call TranscriptFoundation Medicine's (FMI) CEO Troy Cox on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 8:32 AM
Foundation Medicine: 1Q Earnings SnapshotFoundation Medicine: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 8:32 AM
Edited Transcript of FMI earnings conference call or presentation 2-May-18 8:30pm GMTEdited Transcript of FMI earnings conference call or presentation 2-May-18 8:30pm GMT
finance.yahoo.com - May 3 at 8:32 AM
Foundation Medicine Announces 2018 First Quarter Results and Recent HighlightsFoundation Medicine Announces 2018 First Quarter Results and Recent Highlights
finance.yahoo.com - May 2 at 5:21 PM
Head to Head Contrast: Invitae (NVTA) versus Foundation Medicine (FMI)Head to Head Contrast: Invitae (NVTA) versus Foundation Medicine (FMI)
www.americanbankingnews.com - May 2 at 3:24 PM
Foundation Medicine Launches Gene Expression Profiling Program to Identify Known and Novel Biomarkers in Advanced CancerFoundation Medicine Launches Gene Expression Profiling Program to Identify Known and Novel Biomarkers in Advanced Cancer
finance.yahoo.com - May 2 at 8:16 AM
Foundation Medicine (FMI) Raised to "Buy" at BidaskClubFoundation Medicine (FMI) Raised to "Buy" at BidaskClub
www.americanbankingnews.com - May 1 at 9:08 AM
Foundation Medicine (FMI) Scheduled to Post Quarterly Earnings on MondayFoundation Medicine (FMI) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 8:54 AM
BRIEF-Foundation Medicines New Liquid Biopsy Assay Granted Breakthrough Device Designation By US FDABRIEF-Foundation Medicine's New Liquid Biopsy Assay Granted Breakthrough Device Designation By US FDA
www.reuters.com - April 28 at 5:21 PM
Foundation Medicine (FMI) Expected to Announce Quarterly Sales of $44.68 MillionFoundation Medicine (FMI) Expected to Announce Quarterly Sales of $44.68 Million
www.americanbankingnews.com - April 28 at 1:54 AM
BRIEF-Dian Diagnostics In Separate Agreements With Foundation Medicine, F. Hoffmann-La RocheBRIEF-Dian Diagnostics In Separate Agreements With Foundation Medicine, F. Hoffmann-La Roche
finance.yahoo.com - April 27 at 8:27 AM
 Analysts Expect Foundation Medicine (FMI) Will Announce Earnings of -$1.13 Per Share Analysts Expect Foundation Medicine (FMI) Will Announce Earnings of -$1.13 Per Share
www.americanbankingnews.com - April 26 at 11:14 PM
Foundation Medicine (FMI) Says New Liquid Biopsy Assay Granted Breakthrough Device DesignationFoundation Medicine (FMI) Says New Liquid Biopsy Assay Granted Breakthrough Device Designation
www.streetinsider.com - April 26 at 8:27 AM
Foundations new liquid biopsy test designated for accelerated review in U.S.Foundation's new liquid biopsy test designated for accelerated review in U.S.
seekingalpha.com - April 26 at 8:27 AM
Foundation Medicine’s New Liquid Biopsy Assay Granted Breakthrough Device Designation by U.S. Food and Drug AdministrationFoundation Medicine’s New Liquid Biopsy Assay Granted Breakthrough Device Designation by U.S. Food and Drug Administration
finance.yahoo.com - April 26 at 8:27 AM
Foundation Medicine: To Profit From The Increasing Trend Of Personalized TreatmentFoundation Medicine: To Profit From The Increasing Trend Of Personalized Treatment
seekingalpha.com - April 23 at 9:00 AM
Foundation Medicine (FMI) Receives Average Rating of "Hold" from AnalystsFoundation Medicine (FMI) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 20 at 1:42 AM
Insider Selling: Foundation Medicine (FMI) Insider Sells 3,283 Shares of StockInsider Selling: Foundation Medicine (FMI) Insider Sells 3,283 Shares of Stock
www.americanbankingnews.com - April 18 at 7:46 PM
Foundation Medicine (FMI) Director Sells $261,275.00 in StockFoundation Medicine (FMI) Director Sells $261,275.00 in Stock
www.americanbankingnews.com - April 18 at 7:29 PM
Foundation Medicine (FMI) CFO Sells $256,260.70 in StockFoundation Medicine (FMI) CFO Sells $256,260.70 in Stock
www.americanbankingnews.com - April 18 at 7:28 PM
Adding Mercks Keytruda To Chemo Halves Death Risk For Lung Cancer PatientsAdding Merck's Keytruda To Chemo Halves Death Risk For Lung Cancer Patients
www.forbes.com - April 17 at 8:27 AM
Foundation Medicine Announces Timing for First Quarter 2018 Financial Results and Conference CallFoundation Medicine Announces Timing for First Quarter 2018 Financial Results and Conference Call
finance.yahoo.com - April 17 at 8:27 AM
Vineti Completes $33.5 Million in Series B Financing to Accelerate Patient Access to Cell and Gene TherapiesVineti Completes $33.5 Million in Series B Financing to Accelerate Patient Access to Cell and Gene Therapies
globenewswire.com - April 16 at 9:15 AM
Foundation Medicine (FMI) Stock Rating Lowered by BidaskClubFoundation Medicine (FMI) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 14 at 10:53 PM
Foundation Medicine (FMI) Upgraded by BidaskClub to "Sell"Foundation Medicine (FMI) Upgraded by BidaskClub to "Sell"
www.americanbankingnews.com - April 12 at 6:46 PM
$44.68 Million in Sales Expected for Foundation Medicine (FMI) This Quarter$44.68 Million in Sales Expected for Foundation Medicine (FMI) This Quarter
www.americanbankingnews.com - April 12 at 5:54 AM
Foundation Medicine (FMI), Collaborators Present New Findings Supporting Tissue- and Blood-based Comprehensive Genomic ProfilingFoundation Medicine (FMI), Collaborators Present New Findings Supporting Tissue- and Blood-based Comprehensive Genomic Profiling
www.streetinsider.com - April 11 at 5:24 PM
-$1.13 EPS Expected for Foundation Medicine (FMI) This Quarter-$1.13 EPS Expected for Foundation Medicine (FMI) This Quarter
www.americanbankingnews.com - April 10 at 1:27 AM
Cancer Treatment Centers of America and Foundation Medicine Launch Joint Educational Campaign to Raise Consumer Awareness of Precision Medicine Approaches in Cancer CareCancer Treatment Centers of America and Foundation Medicine Launch Joint Educational Campaign to Raise Consumer Awareness of Precision Medicine Approaches in Cancer Care
finance.yahoo.com - April 9 at 5:24 PM

SEC Filings

Foundation Medicine (NASDAQ:FMI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Foundation Medicine (NASDAQ:FMI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Foundation Medicine (NASDAQ FMI) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.